Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Appendix 4E and FY23 Financial Report

Thursday, August 31, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress with its BetaBart (RV-01) program, having dosed the first patient in a Phase 1/2a clinical study. The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared across four programs, indicating a strong pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• Periodic Reports , Price Sensitive
• August 31, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• July 17, 2024
• Announcements
• June 11, 2025
• Announcements
• September 28, 2023
• Announcements
• August 24, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the status of BetaBart (RV-01)?

BetaBart (RV-01) has entered a Phase 1/2a clinical study.

Did Radiopharm receive any FDA approvals?

Yes, Radiopharm received IND approval from the US FDA for a therapeutic study.

What updates has Radiopharm provided?

Radiopharm has shared positive clinical updates across four programs.

When was the first patient dosed?

The first patient was dosed in the Phase 1/2a clinical study recently.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Aug 31, 2023